Dr. Wendy Levin is a Hematologist and Oncologist with more than 15 years of leadership experience in the biotech and diagnostic industries, spanning a broad range of disease indications, diagnostic targets, and early to late phase clinical development. Wendy has provided strategic and executional support for private pre-IPO start-ups to Fortune 500 publicly traded companies and investment firms. In these senior leadership roles, she led regulatory interactions, executed clinical advisory boards and provided global clinical and biomarker translational leadership for all phases of therapeutic development. Wendy’s first role in biopharma was leading the translational and clinical development of Daurismo from pre-IND to designing the FDA registration trial in elderly unfit acute myeloid leukemia (AML) at Pfizer. She subsequently served as vice president and acting CMO of two small publicly traded companies, where she led clinical development and medical affairs. She currently serves as Chief Medical Officer (CMO) for Biofidelity, a clinical stage diagnostics company whose mission is to transform human health by unleashing the potential of genomics. She began her undergraduate and graduate study at the University of California Los Angeles (UCLA), where, under the guidance of Dr Dennis J. Slamon, she co-authored the first publications on HER-2/neu in breast and ovarian cancers. This pivotal work led to the development of the cancer therapeutic Herceptin, which has transformed breast cancer care. The full body of work has been recognized by the Lasker award and has been considered for nomination for the Nobel Prize. Wendy completed her Internal Medicine residency at University of Southern California (LAC + USC), and her Hematology/Oncology Fellowship at the University of Washington/Fred Hutchinson Cancer Research Center in Seattle.